Safety Overview: What Every Patient Should Know Before Starting

The Safest Starting Point Is Uncertainty Made Visible

Limb lengthening combines major orthopedic surgery with weeks of controlled distraction and months of rehabilitation and monitoring. Internal devices remove pin-site exposure but do not remove bone, joint, nerve, vascular, infection, implant, anesthesia, or reoperation risk. No published percentage can substitute for a provider's transparent outcomes for the exact procedure being proposed.

Why Published Rates Differ

Studies mix reconstructive and cosmetic indications, children and adults, femur and tibia, external fixators and different nails, and different definitions of a reportable event. Some count per patient; others count per segment, implant, or operation. Follow-up length also changes what can be detected. Reviews are useful for identifying categories of risk, but pooled rates should not be presented as a universal forecast. ^[1][2][3]

No Reported Deaths Does Not Mean Zero Mortality

A 2025 meta-analysis included seven heterogeneous observational studies totaling 489 cosmetic-lengthening patients and reported no procedure-related deaths in those cohorts. That sample cannot reliably estimate a rare event, and absence of an observed event is not evidence that the risk is zero. The same caution applies when comparing its external-fixator and internal-nail groups. ^[3]

Do Not Turn the Frost Study Into a Per-Millimeter Calculator

The 2023 Frost cohort found complications in 53% of patients across 314 FITBONE and PRECICE nails with mixed indications. Its crude model estimated a 1% increase in risk per millimeter, but after adjustment the confidence interval included no effect and the authors stated that the adjusted analysis provided no evidence that amount lengthened increased risk. ^[2]

Risk Planning That Can Be Verified

• Provider and facility: credentials, hospital privileges, annual case volume, emergency coverage, and outcome data for the proposed segment, device, and indication.
• Device: exact model and diameter, current instructions, regulatory and recall status, load limits, known failure modes, and removal plan.
• Monitoring: who reviews serial images and joint or nerve findings, how quickly results are reviewed, and what triggers slowing, pausing, reversal, or surgery.
• Rehabilitation: local therapist coordination, measurable motion and mobility targets, caregiver needs, and escalation when targets are missed.
• Remote care: after-hours contact, local emergency pathway, medical records, implant documentation, and funding for delayed travel or unplanned return.

Informed Consent Is an Ongoing Process

Consent should explain expected benefits, material risks, alternatives including no surgery, uncertainty, the possibility of stopping before the planned target, additional operations, and who is responsible for complications after discharge or international travel. A signed form is not enough when the device, amount, or care plan changes. ^[4]

Regulatory Status Must Be Checked Near the Date of Surgery

The FDA states that stainless-steel Precice devices including STRYDE remain recalled and should not be implanted. A separate Class II recall covers identified PRECICE MAX catalog and lot combinations and remained open when the FDA record was updated on July 14, 2026. Verify the exact model, UDI or lot, current instructions, and regulator and manufacturer status near consent because a product-family name alone does not establish whether a particular unit is affected. ^[5][6]

Minimum Information to Have Before Committing

• A written procedure, implant, load, distraction, imaging, therapy, and removal plan.
• Provider-specific outcomes with clear denominators, severity definitions, and follow-up.
• A red-flag and after-hours plan that works where recovery will occur.
• A full financial plan for routine care, prolonged recovery, and revision treatment.
• Time to obtain an independent specialist opinion without pressure or expiring-price tactics.